A North Texas startup focused on attention deficit hyperactivity disorder that generated more than $10 million in revenue in just over a year has launched a second product that it hopes will help boost its position as a leader in treating the brain condition.

Grand Prairie-based Neos Therapeutics announced Tuesday that Cotempla XR-ODTTM is now for sale in select markets. Cotempla is the second medication being sold that uses Neos' proprietary extended-release, orally disintegrating tablet technology.

Neos did not specify which markets the drug is sold in now; however, the product will be available nationwide in October.

["Not Found"]

The dissolvable tablets are Food and Drug Administration-approved to help stimulate the central nervous system of patients and control symptoms like inattention and impulsive behavior.

Sales have spiked quickly for Neos since it went public in 2015, a positive sign for investors.

The company's first publicized drug — Adzenys XR-ODT, an amphetamine akin to Adderall — has generated more than $7.3 million in revenue so far this year, and over $10.2 million since the product first came to market in May 2016.

A sales force of about 125 people helped boost the presence of that fruit-flavored, candy-like dissolvable drug, in the offices of "high volume prescribers," Vipin Garg, the CEO and president told investors in August. Adzenys is currently approved for use in children ages 6 to 17.

However, Tom McDonnell, chief commercial officer, also noted that some physicians have extended the age range and Neos has refocused some of its sales efforts on the adult market.

As of mid-July, more than 114,000 prescriptions had been filled for Adzenys since the launch, Neos executives told investors.

Neos is hoping the success and feedback it has received for Adzenys will help bolster sales of its latest product, Cotempla, a methylphenidate akin to Ritalin, that gained FDA approval in June.

This spring the company reported a loss of $18.4 million for the fourth quarter of 2016. Neos had spent $49.3 million on marketing alone, and drug research and development costs were also high.

In June, Neos announced that it had raised approximately $34.5 million in a public offering, which it said could help the company reach positive cash-flow status soon.